{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fquadshot-news-podcast.simplecast.com%2Fepisodes%2F1272025-rtog-0920-bYMxbdik","width":444,"version":"1.0","type":"rich","title":"1.27.2025 - RTOG 0920","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/d4956b26-f7a3-4f47-a83d-9293649d65c8/ec08e780-4e06-4c01-8109-4e894d682296/qs_sqaure.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/4b43b29f-eb17-4c7a-81e9-3db8013f298d\" height=\"200\" width=\"100%\" title=\"1.27.2025 - RTOG 0920\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Check out this week's QuadCast as we highlight the results of RTOG 0920 for adjuvant therapy in H&N cancer, the benefit of bone protective agents in patients receiving radium 223 + enzalutamide, the benefit of incorporating counseling into smoking cessation strategies, and more."}